High concentrations of thyroid hormones in the presence of unsuppressed thyroid stimulating hormone (TSH) can be due to either thyroidhormone resistance, TSH-secreting pituitary adenomas or thyroid hormone autoantibodies, causing spuriously increased or decreased thyroid hormone concentrations depending on the separation procedure used.' This can lead to an erroneous evaluation of thyroid status, and sometimes to inappropriate and potentially harmful therapy.i We report a man in whom thyroid hormone autoantibodies led to an incorrect diagnosis of inappropriate secretion of thyrotropin, unnecessary treatment, iatrogenic subclinical hypothyroidism and postponement of surgery for inguinal hernia.
CASE HISTORY
A 65-year-old man was admitted to the hospital because of goitre and high serum concentrations of free thyroxine (FT4), total thyroxine (TT4), total triiodothyronine (TT3) and unsuppressed TSH. He had a goitre since the age of 50 and had no signs or symptoms of thyroid dysfunction. He had received a presumptive diagnosis of inappropriate secretion of thyrotropin and had been treated with carbimazole (90 mg daily), bromocriptine (7,5 mg daily) and levothyroxine (lOOj.lg daily) until admission. In the referring centre the following studies had been performed: a scintigraphic thyroid study (no tracer accumulation in the right lobe), a thoracic computerized tomography (lateral tracheal shift) and a cranial magnetic resonance imaging (normal). He suffered from right inguinal hernia and surgery was postponed because of 'extremely abnormal thyroid function'. On admission, the physical examination was unremarkable except for a nodule in his right thyroid lobe (3 x 3 ern). Fine Correspondence: Rosa Corcoy MO.
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needle aspiration of the thyroid nodule showed a benign pattern.
Laboratory tests on admission, 48 h after stopping drug therapy were normal except for thyroid function tests which were FT4 31 pmolj L (reference range 9·5-20), FT3 15 pmol/L (4-8), and TSH 6-46m1UjL (0'25-5'0). Serum total and free thyroid hormone concentrations were measured by competitive chemiluminiscent immunoassays using the Ciba Corning automated chemiluminiscence system (ACS: 180™, Ciba Corning Diagnostics Corp, Medfield, MA, USA). Anti-thyroglobulin and anti-microsomal antibodies were negative. The TRH test showed a sixfold increase of the TSH concentration from 6·46mIU/L at time 0 to 35·9mIU/L at 30 min. Prolactin, LH, FSH, testosterone, serum cortisol and urinary free cortisol were within the reference range. Two months after discontinuing all drugs, serum thyroid hormone concentrations were: FT4 32 pmol/L, TT4 245 mmoljL (80140), FT3 13'7pmoljL and TSH 2·3mIU/L. A TSH suppression test with a single oral dose of 300 fig of T3 was performed and TSH decreased from 1·51 mIUjL to 0'15mIUjL 48h after, indicating a normal TSH suppression.' The TSH circadian rhythm was normal. There was no evidence of mouse heteroantibodies interfering in TSH measurement (TSH was 2·3m1UjL in whole serum, and 2·4mIU/L after addition of non-immune mouse serum). Finally, we assessed the presence of thyroid autoantibodies by incubating 1"5I_T4 and 125I_T3 with patient serum and precipitating immunoglobulins with polyethylcneglycol". Control sera bound 5% of both mI-T4 and 1"5I_T3, whereas the patient's serum bound 30°1., of mI_T4 and 12·5% of 125I_T3.
DISCUSSION
Since thyroid hormone autoantibodies were first reported, there have been reports of their existence in patients with a variety of thyroid disorders like primary hypothyroidism, hyperthyroidism, carcinoma, goitre and nonthyroid autoimmune conditions.e" Their frequency is as high as 64% among patients with biochemical thyroid results contradictory with clinical status" and the incidence of autoantibody interference in analogue FT4 and/or FT3 measurement has been estimated to be one in 2460. 7 They have also been reported in up to 1·8% healthy Japanese subjects, although in this case they do not seem to influence the measurement of thyroid hormones." The detection of thyroid autoantibodies is more efficient with methods using thyroid hormone analogues'i? and the prevalence of autoantibodies against T3 is somewhat higher than that against T4 or both of thern? In general, although thyroid hormone autoantibodies may coexist with thyroid dysfunction, they do not alter thyroid function per .I'e. 10 Generally, the patients are female (75%) and have a high prevalence of anti thyroglobulin antibodies (65%),5 conditions which were not present in the patient reported.
After demonstrating that the patient serum was able to bind significant amounts of thyroid hormones, serum concentrations of these hormones were no longer used for monitoring his thyroid function status. The TSH concentration, in the range of subclinical hypothyroidism on admission, when the patient was under multiple drug therapy, fell to normal values two months after discontinuing all drugs indicating a restoration of normal thyroid function. Inadequate and potentially harmful therapy has been described both in patients with inappropriate secretion of thyrotropin 11 and thyroid hormone autoantibodies.? Although this patient did not suffer from serious iatrogenic disease, he was denied surgery for his hernia because of incorrect evaluation of his thyroid function.
In conclusion, the patient described demonstrates the importance of investigating thyroid hormone autoantibodies before establishing a diagnosis of inappropriate secretion of thyrotropin. Their presence should be suspected either by the laboratory (discrepant T4 and TSH results), or by the clinician (T4 and TSH not compatible with the clinical condition). Whenever this is the case, the serum should be reevaluated for thyroxin and/or triiodothyronine binding. Thyroid hormone autoantibodies are infrequent but we must bear them in mind to offer proper diagnosis and therapy to the few patients who present with this condition.
